Clinical Trials Browser

Triple Negative Breast Neoplasms × talimogene laherparepvec × Clear all

NCT02779855 2026-03-10

Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

Phase 1/2 Completed

50 enrolled 12 charts

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Ductal, Triple Negative Breast Neoplasms

NCT03256344 2024-05-14

Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases

Phase 1 Completed

36 enrolled 16 charts

BreastGastrointestinal

Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT04185311 2023-08-15

Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted

Phase 1 Terminated

Breast Carcinoma In Situ, Triple Negative Breast Neoplasms